Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel POC Coagulometer with Lab-Like Precision to Revolutionize Coagulation Testing

By LabMedica International staff writers
Posted on 20 Sep 2023

In emergency settings, when patients arrive with a bleed or require urgent surgery, doctors rely solely on clinical judgment to determine if a patient is adequately anticoagulated for reversal treatment. More...

Until now, there was no point-of-care (POC) diagnostic tool available that could provide immediate insights into a patient's coagulation status, especially for those on direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Now, a novel POC coagulometer offers a real-time, comprehensive view of a patient's clotting status right in the emergency room.

Perosphere Technologies (Danbury, CT, USA) is engaged in the further development and commercialization of a novel POC coagulometer, known as the Perosphere Technologies POC Coagulometer. This device is unique in its ability to promptly and accurately assess clotting times across various types of anticoagulant medications, including DOACs. It requires only 14 microliters of fresh whole blood and yields easy-to-interpret clotting time results with lab-like precision in 3-8 minutes.

This rapid diagnostic capability can significantly influence timely and accurate treatment decisions, setting a new benchmark for emergency care for patients at risk of bleeding. Its compact design and flexibility make it suitable for use not just in emergency departments and ambulances but also across various healthcare settings like hospitals, clinics, surgical centers, physician offices, and pharmacies. While the POC Coagulometer has received the CE Mark for use in the European Union, it is still pending approval in the United States.

“Perosphere Technologies aims to revolutionize coagulation testing by providing healthcare professionals with accurate and timely results,” said Dr. Stefan Zappe, Principal Investigator and Chief Technology Officer at Perosphere Technologies. “By providing physicians with the tools to make faster, better-informed treatment decisions, our technology has strong potential to significantly enhance patient care.”

Related Links:
Perosphere Technologies 


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.